Abstract: Provided herein are multiplex methods for detecting the presence or absence and amount of variants of a plurality of target nucleic acid species having low-abundance variants and high-abundance variants.
Abstract: Methods of labeling or barcoding molecules within one or more portions of a plurality of cells are provided. Kits and systems for labeling or barcoding molecules within one or more portions of a plurality of cells are also provided. The methods, kits, and systems may utilize photo-controlled adapter sequences, nucleic acids tags, and/or linkers.
Type:
Grant
Filed:
February 10, 2017
Date of Patent:
April 28, 2020
Assignee:
University of Washington
Inventors:
Georg Seelig, Anna Kuchina, Alexander B. Rosenberg
Abstract: Under one aspect, a composition includes a substrate; a first polynucleotide coupled to the substrate; a second polynucleotide hybridized to the first polynucleotide; and a catalyst coupled to a first nucleotide of the second polynucleotide, the catalyst being operable to cause a chemiluminogenic molecule to emit a photon. Under another aspect, a method includes providing a catalyst operable to cause a first chemiluminogenic molecule to emit a photon; providing a substrate; providing a first polynucleotide coupled to the substrate; hybridizing a second polynucleotide to the first polynucleotide; coupling a first quencher to a first nucleotide of the second polynucleotide; and inhibiting, by the first quencher, photon emission by the first chemiluminogenic molecule.
Type:
Grant
Filed:
September 10, 2015
Date of Patent:
April 28, 2020
Assignee:
Illumina, Inc.
Inventors:
Boyan Boyanov, Liangliang Qiang, Kevin L. Gunderson, Kay Klausing, Lea Pickering, Cyril Delattre, Tarun Khurana
Abstract: Methods of labeling, identifying and differentiating microorganisms using functionalized Buckyballs are provided herein. The invention further provides methods for imaging or inhibiting gene expression using functionalized Buckyballs of the invention. The invention also provides a system for labeling, identifying and differentiating microorganisms.
Type:
Grant
Filed:
September 2, 2016
Date of Patent:
April 21, 2020
Assignee:
Board of Regents of the Nevada System of Higher Education, on behalf of the University of Nevada, Reno
Abstract: The present invention relates to the field of epigenetics. More specifically, the present invention provides methods and compositions useful for predicting response to epigenetic drug therapy. As described herein, we have identified a unique signature termed AZA Immune gene set or AIM that differentiates patients with a low immune and high immune signature and is regulated by epigenetic drugs such as demethylating drugs, histone deacetylase inhibitors. In certain embodiments, patients with a high immune signature may benefit from immunotherapies such as anti PD1 or anti PDL1 antibodies or vaccines. In other embodiments, patients with a low immune signature or low AIM would be patients who would then benefit from treatment with epigenetic drugs and then subsequent immunotherapy.
Type:
Grant
Filed:
February 9, 2015
Date of Patent:
April 14, 2020
Assignee:
The Johns Hopkins University
Inventors:
Nita Ahuja, Stephen B. Baylin, Katherine Chiappinelli, Angela Anne Guzzetta, Huili Li, Cynthia Zahnow
Abstract: The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.
Abstract: The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.
Abstract: The invention provides a transgenic Gossypium hirsutum event MON 88702, plants, plant cells, seeds, plant parts, progeny plants, and commodity products comprising event MON 88702. The invention also provides polynucleotides specific for event MON 88702, plants, plant cells, seeds, plant parts, progeny plants, and commodity products comprising polynucleotides for event MON 88702. The invention also provides methods related to event MON 88702.
Type:
Grant
Filed:
November 2, 2016
Date of Patent:
March 31, 2020
Assignee:
Monsanto Technology LLC
Inventors:
Waseem Akbar, Robert S. Brown, Wen C. Burns, Thomas L. Clark, Stanislaw Flasinski, Anilkumar Gowda, Aihong Pan, Xiaohong Shi, Jason W. Stelzer, Kunsheng Wu
Abstract: The present disclosure provides a composition comprising a panel of probes for detecting one or more viruses in a sample. The panel of probes may be used to detect viruses in a biological sample obtained from a subject.
Abstract: Compositions, systems and methods for the diagnosing the risk of acute myocardial infarction are provided. The methods described herein relate to the use of biomarkers, such as gene expression profiles, and analytical tools for providing information to a health care provider or the patient, that is relevant to the cardiovascular health of the patient.
Type:
Grant
Filed:
June 13, 2018
Date of Patent:
March 24, 2020
Assignees:
SCRIPPS HEALTH, ORTHO-CLINICAL DIAGNOSTICS, INC.
Inventors:
Eric J. Topol, Evan Muse, Mark Connelly, Timothy Jatkoe, Haiying Wang
Abstract: Provided are systems, kits, and methods for the quantitative detection of single nucleotide polymorphisms or variants to identify malignant neoplasms. The methods include use of modified oligonucleotide blockers with peptide nucleic acid backbones that hybridize to and block logarithmic amplification of the wild-type alleles of a target, and incorporation of locked nucleic acids into probes that are complementary to a mutant allele of the target sequence to increase specificity. The methods include detection of variants in sequences with high GC content and/or low complexity, such as the TERT promoter, IDH1, BRAF, NRAS, GNAQ, GNA11 and H3F3 A gene variants. The methods include sensitive detection and staging of cancers with low cellularity, and can be used intraoperatively such as for glioma, or to detect cell-free circulating tumor DNA, such as for melanoma.
Type:
Grant
Filed:
December 22, 2015
Date of Patent:
March 17, 2020
Assignees:
THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION
Inventors:
Matthew Meyerson, Ganesh M. Shankar, Joshua M. Francis, Daniel P. Cahill, Mikael L. Rinne
Abstract: The present invention relates generally to a method for assessing nucleic acid methylation, in particular DNA and RNA methylation. More particularly, the present invention relates to a method of either qualitatively or quantitatively assessing, with improved sensitivity, the cytosine methylation of partially methylated DNA or RNA. The method of the present invention is useful in a range of applications including, but not limited to, the diagnosis of conditions or monitoring of developmental phenotypes which are characterised by DNA or RNA methylation changes.
Abstract: A method for identifying target alleles, that includes steps of (a) forming a plurality of stabilized ternary complexes at a plurality of features on an array, wherein the stabilized ternary complexes each has a polymerase, a template nucleic acid having a target allele of a locus, a primer hybridized to the locus, and a next correct nucleotide having a cognate in the locus, wherein either (i) the primer is an allele-specific primer having a 3? nucleotide that is a cognate nucleotide for the target allele, or (ii) the primer is a locus-specific primer and the next correct nucleotide hybridizes to the target allele; and (b) detecting stabilized ternary complexes at the features, thereby identifying the target alleles.
Abstract: Methods of producing single-stranded deoxyribonucleic acids (ssDNAs) are provided. Aspects of the methods include generating a double stranded deoxyribonucleic acid (dsDNA) and then selectively degrading one strand of the dsDNA to produce a ssDNA. ssDNAs produced using methods of the invention find use in a variety of applications, including genomic modification applications. Also provided are compositions, e.g., kits, that find use in practicing various embodiments of the invention.
Type:
Grant
Filed:
June 2, 2017
Date of Patent:
March 10, 2020
Assignee:
Takara Bio USA, Inc.
Inventors:
Hiroyuki Matsumoto, Michael Haugwitz, Andrew Farmer, Magnolia Bostick
Abstract: The present invention relates to detection of cancer, or assessment of risk of development thereof. In particular, the present invention provides compositions and methods detection of field carcinogenesis by identification of ultrastructural and molecular markers in a subject.
Type:
Grant
Filed:
October 9, 2017
Date of Patent:
March 10, 2020
Assignees:
Northwesten University, NorthShore University HealthSystem
Inventors:
Vadim Backman, Hariharan Subramanian, Dhwanil Damania, Hemant Roy, Dhananjay Kunte, Mart Angelo De la Cruz
Abstract: A method (e.g. high resolution melting analysis) of determining of the presence or absence of a target nucleic acid in a sample, e.g. a biological sample, the method comprising steps of:?(a) contacting the sample with a composition comprising?(i) a quaternary ammonium compound, e.g. 3-(trimethoxysilyl) propyl-dimethyl octadecyl ammonium chloride (3-TPAC) or a precursor thereof, in order to release the nucleic acids from said sample; and?(b) contacting the sample with a probe which is capable of interacting with the nucleic acid sequence; and?(c) observing and/or measuring a property of the sample, e.g. fluorescence from a dsDNA binding dye.
Type:
Grant
Filed:
July 28, 2016
Date of Patent:
January 28, 2020
Assignee:
ARCIS BIOTECHNOLOGY HOLDINGS LIMITED
Inventors:
Jan Rogers, Paul Reeves, Carlos Toro Rueda
Abstract: The disclosure provides methods for analyzing rare circulating cells (RCCs) at cellular and molecular level following their detection in non-enriched blood samples, methods of this disclosure serve as diagnostic methods for several disease conditions, including cardiovascular diseases and cancer.
Abstract: Staining nucleotides within chromosomes is an important technique used in cytogenetics to produce a visible karyotype by staining condensed chromosomes. Such techniques are useful, for example, in identifying genetic diseases through the photographic representation of the entire chromosome complement. Prior to the steps of selective dissolving and staining of nucleotides within the chromosomes an aging step is performed to increase the selective solubility between different nucleotides. Within the prior art this aging step is a time consuming process taking several days. Accordingly, it would be beneficial to provide a staining pretreatment method which can be performed in a short period of time.
Abstract: Methods and kits for diagnosing systemic lupus erythematosus (SLE) in a subject are provided. Particularly, the present invention relates to specific oligonucleotide antibody reactivities useful in diagnosing SLE in a subject.
Type:
Grant
Filed:
December 31, 2014
Date of Patent:
January 28, 2020
Assignee:
YEDA RESEARCH AND DEVELOPMENT CO., LTD.
Inventors:
Irun R. Cohen, Eytan Domany, Noam Shental, Ittai Fattal